MEDIX, God. 26 Br. 142 Supplement 1  •  Pregledni članak  •  Gastroenterologija HR ENG

Preporuke za primjenu biološke terapije u bolesnika s upalnim bolestima crijeva tijekom pandemije COVID-19Recommendations for the use of biologic therapy in patients with inflammatory bowel disease during the COVID-19 pandemic period

Željko Krznarić, Marko Brinar, Silvija Čuković Čavka, Nikša Turk, Dora Grgić, Mislav Jelaković, Marina Šabić, Viktor Domislović

Tijekom pandemije COVID-19 učestala su pitanja liječnika i bolesnika o liječenju pacijenata s upalnim bolestima crijeva, odnosno ulceroznim kolitisom i Crohnovom bolesti. Broj znanstvenih radova i spoznaja o infekciji SARS-CoV-2 virusom raste eksponencijalno, kao i broj registriranih studija o primjeni različitih terapija u liječenju infekcije COVID-19. U ovom sažetom pregledu obuhvatili smo naše preporuke i pristup liječenju pacijenata s upalnim bolestima crijeva tijekom razdoblja pandemije. Iako navedene preporuke pružaju privremeni okvir za postupanje i odabir primjerene terapije, potrebno je naglasiti kako konačnu odluku o terapiji donosimo uzimajući u obzir niz čimbenika, uključujući dob bolesnika i komorbiditet. Neadekvatna terapija te zakašnjela terapijska intervencija mogu značajno nadmašiti rizik potencijalne SARS-CoV-2 infekcije

Ključne riječi:
COVID-19; Crohnova bolest; IBD; SARS-CoV-2; ; ulcerozni kolitis

Članak je dostupan u cijelosti u PDF formatu

PREUZMI PDF

During the COVID-19 infection, questions from physicians and patients about the treatment of patients with inflammatory bowel disease were frequent. The number of scientific papers and findings on SARS-CoV-2 virus infection is growing exponentially, as is the number of registered studies on the application of various therapies in the treatment of COVID-19 infection. In this review paper, we have included our recommendations and approach in treating patients with inflammatory bowel disease during the pandemic. Although these recommendations provide a temporary framework for treatment and selection of adequate therapy, it should be emphasized that the final decision on therapy is made taking into account a number of factors including the age of the patient and comorbidity. Inadequate therapy and delayed therapeutic intervention can significantly outweigh the risk of potential SARS-CoV-2 infection.

Key words:
COVID-19; Crohn_s disease; IBD; SARS-CoV-2; ulcerative colitis